Idera Pharmaceuticals, Inc.

Symbol: IDRA

NASDAQ

0.425

USD

Market price today

  • -0.0592

    P/E Ratio

  • 0.0048

    PEG Ratio

  • 26.50M

    MRK Cap

  • 0.00%

    DIV Yield

Idera Pharmaceuticals, Inc. (IDRA) Stock Price & Analysis

Shares Outstanding

52.8M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.23%

Return on Equity

-1.17%

Return on Capital Employed

-0.37%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Vincent Milano
Full-time employees:13
City:Exton
Address:505 Eagleview Blvd Ste 212
IPO:1996-01-25
CIK:0000861838

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

General Outlook

In simple terms, Idera Pharmaceuticals, Inc. has 52.798 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.231% return, is a testament to Idera Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Idera Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.174%. Furthermore, the proficiency of Idera Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.370% return on capital employed.

Stock Prices

Idera Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.3162, while its low point bottomed out at $0.306. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Idera Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing IDRA liquidity ratios reveals its financial health of the firm. The current ratio of 83.38% gauges short-term asset coverage for liabilities. The quick ratio (75.86%) assesses immediate liquidity, while the cash ratio (56.22%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio83.38%
Quick Ratio75.86%
Cash Ratio56.22%

Profitability Ratios

The effective tax rate stands at 21.29%, revealing its tax efficiency. The net income per EBT, 78.71%, and the EBT per EBIT, 100.69%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate21.29%
Net Income per EBT78.71%
EBT per EBIT100.69%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.83, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding76
Days of Payables Outstanding335
Payables Turnover1.09

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -7.52, and free cash flow per share, -7.52, depict cash generation on a per-share basis. The cash per share value, 3.70, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-7.52
Free Cash Flow per Share-7.52
Cash per Share3.70
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-43.74
Short Term Coverage Ratio-104.68

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.55%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.05, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.68%, and total debt to capitalization, 4.52%, ratios shed light on its capital structure. An interest coverage of -144.48 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.55%
Debt Equity Ratio0.05
Long Term Debt to Capitalization2.68%
Total Debt to Capitalization4.52%
Interest Coverage-144.48
Cash Flow to Debt Ratio-43.74
Company Equity Multiplier8.55

Per Share Data

Net income per share, 49.31, reflects the portion of profit attributed to each share. The book value per share, 14.80, represents the net asset value distributed per share, while the tangible book value per share, 14.80, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share49.31
Book Value Per Share14.80
Tangible Book Value Per Share14.80
Shareholders Equity Per Share14.80
Interest Debt Per Share0.38

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -12,509,030, captures the company's total value, considering both debt and equity. Income quality, -0.25, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value-12,509,030
Income Quality-0.25
Graham Number128.15
Return on Tangible Assets281.35%
Graham Net Net13.64
Working Capital29,176,000
Tangible Asset Value29,453,000
Net Current Asset Value28,627,000
Average Payables447,000
ROIC89.87%
ROE3.33%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.12, and the price to book ratio, 0.12, reflect the market's valuation relative to the company's book value.

cards.indicatorcards.value
Price Book Value Ratio0.12
Price to Book Ratio0.12
Price Cash Flow Ratio-0.06
Enterprise Value Multiple-0.39
Price Fair Value0.12
Price to Operating Cash Flow Ratio-0.06
Price to Tangible Book Ratio0.65
Enterprise Value Over EBITDA-0.13
EV to Operating Cash Flow0.51
Earnings Yield508.82%
Free Cash Flow Yield-127.59%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Idera Pharmaceuticals, Inc. (IDRA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.059 in 2024.

What is the ticker symbol of Idera Pharmaceuticals, Inc. stock?

The ticker symbol of Idera Pharmaceuticals, Inc. stock is IDRA.

What is company IPO date?

IPO date of Idera Pharmaceuticals, Inc. is 1996-01-25.

What is company current share price?

Current share price is 0.425 USD.

What is stock market cap today?

The market cap of stock today is 26501046.000.

What is PEG ratio in 2024?

The current 0.005 is 0.005 in 2024.

What is the number of employees in 2024?

In 2024 the company has 13.